EA025483B1 - Внутривенный способ лечения сезонного гриппа - Google Patents
Внутривенный способ лечения сезонного гриппа Download PDFInfo
- Publication number
- EA025483B1 EA025483B1 EA200870263A EA200870263A EA025483B1 EA 025483 B1 EA025483 B1 EA 025483B1 EA 200870263 A EA200870263 A EA 200870263A EA 200870263 A EA200870263 A EA 200870263A EA 025483 B1 EA025483 B1 EA 025483B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- peramivir
- acceptable salt
- compound
- pharmaceutically acceptable
- formula
- Prior art date
Links
- 238000001990 intravenous administration Methods 0.000 title claims abstract description 26
- 206010022000 influenza Diseases 0.000 title claims abstract description 22
- 238000000034 method Methods 0.000 title claims abstract description 21
- 230000001932 seasonal effect Effects 0.000 title claims abstract description 16
- XRQDFNLINLXZLB-CKIKVBCHSA-N peramivir Chemical compound CCC(CC)[C@H](NC(C)=O)[C@@H]1[C@H](O)[C@@H](C(O)=O)C[C@H]1NC(N)=N XRQDFNLINLXZLB-CKIKVBCHSA-N 0.000 claims abstract description 63
- 229960001084 peramivir Drugs 0.000 claims abstract description 63
- 239000003814 drug Substances 0.000 claims abstract description 28
- 150000003839 salts Chemical class 0.000 claims abstract description 25
- 241000282414 Homo sapiens Species 0.000 claims abstract description 19
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims description 37
- 241000700605 Viruses Species 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 14
- 210000002381 plasma Anatomy 0.000 claims description 13
- 241000712461 unidentified influenza virus Species 0.000 claims description 13
- 241000282412 Homo Species 0.000 claims description 9
- 208000024891 symptom Diseases 0.000 claims description 7
- 208000036142 Viral infection Diseases 0.000 claims description 5
- 230000009385 viral infection Effects 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 abstract description 3
- 102000005348 Neuraminidase Human genes 0.000 abstract 1
- 108010006232 Neuraminidase Proteins 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 22
- 241000699670 Mus sp. Species 0.000 description 16
- 241001465754 Metazoa Species 0.000 description 10
- 208000015181 infectious disease Diseases 0.000 description 10
- 230000000840 anti-viral effect Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 238000002347 injection Methods 0.000 description 6
- 239000007924 injection Substances 0.000 description 6
- 238000007918 intramuscular administration Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 230000036470 plasma concentration Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000002253 acid Substances 0.000 description 4
- 239000006185 dispersion Substances 0.000 description 4
- 238000010253 intravenous injection Methods 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002035 prolonged effect Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 208000037797 influenza A Diseases 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- KPGXRSRHYNQIFN-UHFFFAOYSA-N 2-oxoglutaric acid Chemical compound OC(=O)CCC(=O)C(O)=O KPGXRSRHYNQIFN-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 230000005526 G1 to G0 transition Effects 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 206010025080 Lung consolidation Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000005323 carbonate salts Chemical class 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 125000005908 glyceryl ester group Chemical group 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 239000006207 intravenous dosage form Substances 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 238000009520 phase I clinical trial Methods 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US77274806P | 2006-02-13 | 2006-02-13 | |
| PCT/US2006/013535 WO2007117241A1 (en) | 2006-04-12 | 2006-04-12 | Intramuscular antiviral treatments |
| PCT/US2007/003755 WO2007095218A1 (en) | 2006-02-13 | 2007-02-12 | Intravenous antiviral treatments |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA200870263A1 EA200870263A1 (ru) | 2009-06-30 |
| EA025483B1 true EA025483B1 (ru) | 2016-12-30 |
Family
ID=38169715
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA200870263A EA025483B1 (ru) | 2006-02-13 | 2007-02-12 | Внутривенный способ лечения сезонного гриппа |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP1986626A1 (enExample) |
| JP (3) | JP2009538822A (enExample) |
| KR (9) | KR102475176B1 (enExample) |
| CN (1) | CN104784166A (enExample) |
| AU (1) | AU2007215156A1 (enExample) |
| BR (1) | BRPI0707769A2 (enExample) |
| CA (1) | CA2642260C (enExample) |
| EA (1) | EA025483B1 (enExample) |
| HK (1) | HK1212250A1 (enExample) |
| MX (2) | MX393640B (enExample) |
| MY (1) | MY166063A (enExample) |
| WO (1) | WO2007095218A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0707769A2 (pt) * | 2006-02-13 | 2011-05-10 | Biocryst Pharm Inc | tratamentos antivirais intravenosos |
| CN101367750B (zh) * | 2007-08-14 | 2012-05-23 | 中国人民解放军军事医学科学院毒物药物研究所 | (1s,2s,3s,4r)-3-[(1s)-1-乙酰氨-2-乙基-丁基]-4-胍基-2-羟基-环戊基-1-羧酸水合物及其医药用途 |
| KR20220033561A (ko) | 2020-09-07 | 2022-03-17 | 주식회사 경보제약 | 페라미비르 화합물을 포함하는 프리믹스 제형의 제약학적 조성물 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001097792A2 (en) * | 2000-06-22 | 2001-12-27 | Glaxosmithkline K K | Neuraminidase inhibitors in the treatment of equine influenza virus infection |
| US6562861B1 (en) * | 1997-12-17 | 2003-05-13 | Biocryst Pharmaceuticals, Inc. | Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CZ412898A3 (cs) * | 1996-06-14 | 1999-08-11 | Biocryst Pharmaceuticals, Inc. | Substituované cyklopentanové sloučeniny, použitelné jako inhibitory neuraminidázy |
| BRPI0707769A2 (pt) * | 2006-02-13 | 2011-05-10 | Biocryst Pharm Inc | tratamentos antivirais intravenosos |
-
2007
- 2007-02-12 BR BRPI0707769-6A patent/BRPI0707769A2/pt not_active Application Discontinuation
- 2007-02-12 KR KR1020217035812A patent/KR102475176B1/ko active Active
- 2007-02-12 KR KR1020197017311A patent/KR102194015B1/ko active Active
- 2007-02-12 AU AU2007215156A patent/AU2007215156A1/en not_active Abandoned
- 2007-02-12 CN CN201510115375.7A patent/CN104784166A/zh active Pending
- 2007-02-12 KR KR1020087022406A patent/KR20080096829A/ko not_active Ceased
- 2007-02-12 EA EA200870263A patent/EA025483B1/ru unknown
- 2007-02-12 JP JP2008554421A patent/JP2009538822A/ja not_active Withdrawn
- 2007-02-12 KR KR1020217018500A patent/KR102323339B1/ko active Active
- 2007-02-12 CA CA2642260A patent/CA2642260C/en active Active
- 2007-02-12 WO PCT/US2007/003755 patent/WO2007095218A1/en not_active Ceased
- 2007-02-12 KR KR1020187005451A patent/KR101992585B1/ko not_active Ceased
- 2007-02-12 KR KR20147030611A patent/KR20140132778A/ko not_active Ceased
- 2007-02-12 KR KR1020227042429A patent/KR20230003248A/ko not_active Ceased
- 2007-02-12 KR KR1020167030296A patent/KR20160129105A/ko not_active Ceased
- 2007-02-12 MX MX2020002008A patent/MX393640B/es unknown
- 2007-02-12 EP EP07750583A patent/EP1986626A1/en not_active Ceased
- 2007-02-12 MX MX2008010394A patent/MX2008010394A/es active IP Right Grant
- 2007-02-12 KR KR1020207036259A patent/KR102267754B1/ko active Active
-
2008
- 2008-08-13 MY MYPI20083086A patent/MY166063A/en unknown
-
2013
- 2013-08-26 JP JP2013174479A patent/JP6073202B2/ja active Active
-
2015
- 2015-07-09 JP JP2015137495A patent/JP2015180695A/ja not_active Withdrawn
-
2016
- 2016-01-14 HK HK16100369.5A patent/HK1212250A1/xx unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6562861B1 (en) * | 1997-12-17 | 2003-05-13 | Biocryst Pharmaceuticals, Inc. | Substituted cyclopentane and cyclopentene compounds useful as neuraminidase inhibitors |
| WO2001097792A2 (en) * | 2000-06-22 | 2001-12-27 | Glaxosmithkline K K | Neuraminidase inhibitors in the treatment of equine influenza virus infection |
Non-Patent Citations (3)
| Title |
|---|
| BANTIA, S. ARNOLD, C.S. PARKER, C.D. UPSHAW, R. CHAND, P.: "Anti-influenza virus activity of peramivir in mice with single intramuscular injection", ANTIVIRAL RESEARCH, ELSEVIER BV, NL, vol. 69, no. 1, 1 January 2006 (2006-01-01), NL, pages 39 - 45, XP005212462, ISSN: 0166-3542, DOI: 10.1016/j.antiviral.2005.10.002 * |
| CHAND, P. BANTIA, S. KOTIAN, P.L. EL-KATTAN, Y. LIN, T.H. BABU, Y.S.: "Comparison of the anti-influenza virus activity of cyclopentane derivatives with oseltamivir and zanamivir in vivo", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, GB, vol. 13, no. 12, 2 June 2005 (2005-06-02), GB, pages 4071 - 4077, XP004903742, ISSN: 0968-0896, DOI: 10.1016/j.bmc.2005.03.048 * |
| SORBERA L. A., ET AL.: "ANTI-INFLUENZA NEURAMINIDASE (SIALIDASE) INHIBITOR.", DRUGS OF THE FUTURE, PROUS SCIENCE, ES, vol. 25., no. 03., 1 January 2000 (2000-01-01), ES, pages 249 - 251., XP000940977, ISSN: 0377-8282, DOI: 10.1358/dof.2000.025.03.565302 * |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2020002008A (es) | 2020-07-13 |
| KR20190072681A (ko) | 2019-06-25 |
| KR20230003248A (ko) | 2023-01-05 |
| KR20200143519A (ko) | 2020-12-23 |
| KR102475176B1 (ko) | 2022-12-07 |
| EP1986626A1 (en) | 2008-11-05 |
| CA2642260C (en) | 2016-08-09 |
| JP2013256527A (ja) | 2013-12-26 |
| EA200870263A1 (ru) | 2009-06-30 |
| KR20180024027A (ko) | 2018-03-07 |
| KR101992585B9 (ko) | 2022-09-20 |
| JP6073202B2 (ja) | 2017-02-01 |
| MX393640B (es) | 2025-03-21 |
| JP2009538822A (ja) | 2009-11-12 |
| KR20140132778A (ko) | 2014-11-18 |
| CA2642260A1 (en) | 2007-08-23 |
| KR102323339B1 (ko) | 2021-11-08 |
| KR20160129105A (ko) | 2016-11-08 |
| HK1212250A1 (en) | 2016-06-10 |
| KR101992585B1 (ko) | 2019-06-25 |
| MY166063A (en) | 2018-05-23 |
| WO2007095218A1 (en) | 2007-08-23 |
| KR20080096829A (ko) | 2008-11-03 |
| CN104784166A (zh) | 2015-07-22 |
| KR20210135632A (ko) | 2021-11-15 |
| JP2015180695A (ja) | 2015-10-15 |
| KR20210076189A (ko) | 2021-06-23 |
| KR102194015B1 (ko) | 2020-12-22 |
| AU2007215156A1 (en) | 2007-08-23 |
| BRPI0707769A2 (pt) | 2011-05-10 |
| KR102267754B1 (ko) | 2021-06-23 |
| MX2008010394A (es) | 2009-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2432164T3 (es) | Composición estabilizada que comprende al menos un compuesto adrenérgico | |
| US20080269347A1 (en) | Epinephrine formulations | |
| US11779585B2 (en) | Method for treating coronavirus infections | |
| CN111163764A (zh) | L-肾上腺素的稳定化可注射药物组合物 | |
| EP2635269B1 (en) | A combination composition | |
| JP2023061957A (ja) | 抑うつ障害の処置 | |
| WO2022046976A1 (en) | An epinephrine injection formulation with very low epinephrine concentration and low impurities during its shelf-life | |
| KR102656841B1 (ko) | 레파뮬린의 주사가능한 약제학적 제형 | |
| JP6073202B2 (ja) | 静脈におけるウイルスの治療 | |
| JP2009538822A5 (enExample) | ||
| JPH11511479A (ja) | １，２，４−ベンゾトリアジンオキシド製剤 | |
| WO2026013454A1 (en) | Multi-dose pen of tirzepatide | |
| US20230285434A1 (en) | Method for treating arenaviridae infections | |
| AU2013216632B2 (en) | Intravenous antiviral treatments | |
| JP2009533428A (ja) | 筋肉内抗ウイルス処置 | |
| WO2020025986A1 (en) | Injectable combination of diclofenac sodium and thiocolchicoside |